Showing results (21-30 of 204) with videos related to
Sort By:
Pageof 21
Journal of Hematology & Oncology|July 29, 2015
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practiceGaurav Goel, Weijing SunJournal of Hematology & Oncology|July 16, 2015
Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockadeGaurav Goel, Weijing SunOncology (Williston Park, N.Y.)|October 23, 2003
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I studyWeijing Sun, Daniel HallerChinese Journal of Cancer|September 2, 2016
Gastric cancer: current and evolving treatment landscapeWeijing Sun, Li YanChinese Journal of Cancer|September 6, 2014
Cancer immunotherapy in clinical practice -- the past, present, and futureGaurav Goel, Weijing SunJournal of Hematology & Oncology|May 4, 2015
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the futureGaurav Goel, Weijing SunAnti-Cancer Drugs|June 5, 2002
Docetaxel in advanced gastric cancerDaniel G Haller, Jean-Louis MissetNature Reviews. Clinical Oncology|April 25, 2009
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancerUrsina R Teitelbaum, Daniel G HallerClinical Colorectal Cancer|October 14, 2004
Future directions with angiogenesis inhibitors in colorectal cancerJoshua H Bilenker, Daniel G HallerGastrointestinal Cancer Research : GCR|April 9, 2009
Accomplishments in 2007 in the adjuvant treatment of colorectal cancerAimery de Gramont, Daniel G HallerPageof 21